Forum Markets, Incorporated (ATNF)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ATNF Chart
180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules
PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock.
180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors
PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024. Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning.
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately.
Forum Markets, Incorporated (ATNF) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Forum Markets, Incorporated Profile
| - Industry | - Sector | Lloyd Blair Jordan CEO | NASDAQ (CM) Exchange | 68236V104 CUSIP |
| US Country | 4 Employees | - Last Dividend | 28 Feb 2024 Last Split | - IPO Date |
Overview
180 Life Sciences Corp. is positioned as a pioneering clinical stage biotechnology firm that concentrates its efforts on the invention and development of therapeutic solutions addressing the gap in treatment options for chronic pain, inflammation, fibrosis, and other inflammatory conditions. With its headquarters nestled in Palo Alto, California, the company leverages its extensive expertise in biotechnology to target some of the most challenging medical needs. Through its dedicated research and clinical trials, 180 Life Sciences Corp. aspires to bring forth innovative therapies that can significantly improve the quality of life for patients grappling with these severe health issues.
Products and Services
The various platforms and projects under the umbrella of 180 Life Sciences Corp. include:
- Fibrosis and Anti-TNF Platform - This platform stands out with its completion of phase 2a and 2b proof-of-concept clinical trials, specifically focusing on early-stage Dupuyren's Contracture. Dupuyren's Contracture is a hand condition that progressively worsens, eventually leading to hand function impairment. By targeting this condition, the platform aims to offer a novel therapeutic approach that could significantly mitigate its impact on patients' lives.
- Synthetic Cannabidiol (CBD) Analogs Platform - The company also explores the therapeutic potentials of synthetic cannabinoids through this platform. These are pharmaceutical grade molecules that are either close or distant analogs of non-psychoactive cannabinoids, such as CBD. Their primary purpose is for the treatment of inflammatory diseases and pain. Unlike traditional plant-derived CBD, these synthetic analogs ensure consistent purity and potency, potentially offering a more reliable and effective treatment option.
- a7nAChR Platform - Focusing on the alpha 7 nicotinic acetylcholine receptor, this immune suppressive platform represents another aspect of the company's innovative thrust. It targets a specific pathway known for its role in the inflammatory process, thereby offering a new vantage point in the treatment of inflammatory diseases. By modulating this receptor, the platform could pave the way for groundbreaking therapies in managing inflammation and related disorders.
